Xilio Therapeutics (XLO) EV to FCF (2021 - 2026)

Xilio Therapeutics has disclosed EV to FCF across 6 years of filings, most recently posting 2.65 for Q2 2026.

• In Q2 2026, EV to FCF fell 169.28% year-over-year to 2.65; the TTM figure through Jun 2026 stood at 0.81 (down 120.01% YoY), while the FY2025 annual figure was 11.36, up 1704.77% from the prior year.
• EV to FCF came in at 2.65 for Q2 2026 at Xilio Therapeutics, down from 0.56 in the prior quarter.
• In the past five years, EV to FCF ranged from a high of 29.91 in Q4 2025 to a low of 2.65 in Q2 2026.
• Average EV to FCF over 5 years is 2.35, with a median of 0.46 recorded in 2024.
• Year-over-year, EV to FCF slumped 616.98% in 2024 and soared 3554.36% in 2025.
• Over 5 years, EV to FCF stood at 2.49 in 2022, then fell by 11.64% to 2.2 in 2023, then sank by 62.77% to 0.82 in 2024, then soared by 3554.36% to 29.91 in 2025, then sank by 108.87% to 2.65 in 2026.
• Per Business Quant data, the three most recent EV to FCF figures were 2.65 in Q2 2026, 0.56 in Q1 2026, and 29.91 in Q4 2025.